Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AbbVie Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ABBV
New York
2834
https://www.abbvie.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AbbVie Inc
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
- Apr 26th, 2024 8:08 pm
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
- Apr 26th, 2024 8:07 pm
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
- Apr 26th, 2024 7:15 pm
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
- Apr 26th, 2024 4:10 pm
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
- Apr 26th, 2024 3:02 pm
PCE/Core PCE Numbers Came In Line With Expectations
- Apr 26th, 2024 2:53 pm
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
- Apr 26th, 2024 2:33 pm
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
- Apr 26th, 2024 2:30 pm
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop
- Apr 26th, 2024 1:58 pm
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates Despite Revenue Challenges
- Apr 26th, 2024 1:11 pm
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
- Apr 26th, 2024 12:45 pm
AbbVie tries to reassure investors on Humira biosimilar threat
- Apr 26th, 2024 12:01 pm
Drugmaker AbbVie expects Humira volume erosion to worsen
- Apr 26th, 2024 11:44 am
AbbVie raises annual profit forecast on strong Skyrizi sales
- Apr 26th, 2024 11:36 am
AbbVie Reports First-Quarter 2024 Financial Results
- Apr 26th, 2024 11:35 am
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
- Apr 25th, 2024 8:48 pm
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
- Apr 25th, 2024 12:44 pm
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
- Apr 25th, 2024 12:33 pm
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
- Apr 25th, 2024 12:00 pm
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
- Apr 24th, 2024 4:05 pm
Scroll